TY - JOUR
T1 - The generalizability of trial data; A comparison of β-blocker trial participants with a prospective cohort of women taking β-blockers in pregnancy
AU - Magee, Laura A.
AU - Bull, Shelley B.
AU - Koren, Gideon
AU - Logan, Alexander
N1 - Funding Information:
Supported by grants from the Physicians’ Services Incorporated, Toronto, and CIBA Canada Ltd. LAM was supported by a Duncan Gordon International Fellowship of the Hospital for Sick Children’s Foundation, and a Detweiler Travelling Fellowship from the Royal College of Physicians and Surgeons of Canada. SBB is a National Health Research Scholar of the National Health Research Development Program. GK is a Career Scientist of the Ontario Ministry of Health.
PY - 2001
Y1 - 2001
N2 - Objective: To evaluate the generalizability of randomized controlled trial (RCT) data to obstetric practice, using the example of β-blocker therapy. Study design: Descriptive comparison of characteristics of participants, interventions, and outcomes assessed between a meta-analysis of trials of β-blocker therapy in pregnancy, and a prospective cohort of β-blocker exposed callers to Motherisk, a Teratology Information Service. Results: 72 women (cohort) and 34 trials with 2474 participants (meta-analysis) were compared. The generalizability of trials was limited by an inadequate description of maternal demographics and indications for β-blockers, and a focus on the effectiveness of β-blockers as antihypertensives rather than on reproductive risks. Conclusions: Some of these limitations could be rectified. Others cannot, such as evaluation of teratogenicity (for ethical reasons) or all indications for a drug (for practical reasons). Reference to observational literature is, and will likely remain, necessary to address the 'harm' side of the therapeutic equation in pregnancy.
AB - Objective: To evaluate the generalizability of randomized controlled trial (RCT) data to obstetric practice, using the example of β-blocker therapy. Study design: Descriptive comparison of characteristics of participants, interventions, and outcomes assessed between a meta-analysis of trials of β-blocker therapy in pregnancy, and a prospective cohort of β-blocker exposed callers to Motherisk, a Teratology Information Service. Results: 72 women (cohort) and 34 trials with 2474 participants (meta-analysis) were compared. The generalizability of trials was limited by an inadequate description of maternal demographics and indications for β-blockers, and a focus on the effectiveness of β-blockers as antihypertensives rather than on reproductive risks. Conclusions: Some of these limitations could be rectified. Others cannot, such as evaluation of teratogenicity (for ethical reasons) or all indications for a drug (for practical reasons). Reference to observational literature is, and will likely remain, necessary to address the 'harm' side of the therapeutic equation in pregnancy.
KW - Beta-receptor blocker
KW - Generalizability
KW - Meta-analysis
KW - Pregnancy complications
KW - Randomized controlled trials
UR - http://www.scopus.com/inward/record.url?scp=0035145224&partnerID=8YFLogxK
U2 - 10.1016/S0301-2115(00)00331-6
DO - 10.1016/S0301-2115(00)00331-6
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 11165726
AN - SCOPUS:0035145224
SN - 0301-2115
VL - 94
SP - 205
EP - 210
JO - European Journal of Obstetrics, Gynecology and Reproductive Biology
JF - European Journal of Obstetrics, Gynecology and Reproductive Biology
IS - 2
ER -